Abstract
Inhaled antibiotics and mucolytics can prevent exacerbations and maintain lung function in cystic fibrosis (CF). However, treatment adherence is usually low1-3 (even for cystic fibrosis transmembrane conductance regulator modulators4), which undermines treatment effectiveness.2 Single-center studies1 or studies lacking objective adherence data2 complicate the accurate representation of CF adherence levels. In addition, adherence may be over-estimated by convenience sampling and by adherence definitions that do not account for minimum required treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
